Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Meibomian Gland Dysfunction (Disorder) Clear all
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis

NCT00629590
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Wantagh, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

Meibomian Gland Dysfunction Treatment

NCT04229888
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
LipiFlow, Light Based (Sham) Treatment
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers

NCT02102464
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
LipiFlow treatment
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Morrow, Georgia • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional

Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD

NCT02621593
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
M22-IPL
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Beverly Hills, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tear Film Innovations iLux Safety Study

NCT03055897
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
iLux 2020 System
Device
Lead sponsor
Tear Film Innovations, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

TearCare System to Treat Dry Eye Disease

NCT03857919
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare, LipiFlow
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Scottsdale, Arizona • Laguna Hills, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 10, 2026, 5:48 PM EST
Recruiting No phase listed Observational

A Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract Surgery

NCT07928986
View directory record Official record
Conditions
Dry Eye Syndrome (DES), Meibomian Gland Dysfunction (Disorder)
Interventions
Manual expression of meibomian glands after thermal eyelid therapy
Device
Lead sponsor
Cleveland Eye Clinic
Other
Eligibility
50 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Largo, Florida • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study

NCT03956225
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye Disease
Interventions
Systane iLux® Dry Eye System, LipiFlow® Thermal Pulsation System
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 4 Interventional Results available

Intraductal Meibomian Gland Probing Trial

NCT02256969
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Blephamide, GenTeal PM Night-Time, Meibomian Gland Probing, Sham Meibomian Gland Probing
Drug · Procedure
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional

Safety of Tinted Soft Scleral Eye Shields When IPL is Applied on Eyelids

NCT05168670
View directory record Official record
Conditions
Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
Protection of eyes with tinted soft scleral eye shields
Combination Product
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction

NCT03055832
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
iLux 2020 System, LipiFlow Pulsation System
Device
Lead sponsor
Tear Film Innovations, Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
7
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional

Evaluation of Low-Level Light Therapy on Meibomian Glands Study

NCT05859295
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Red Low-Level Light Therapy
Device
Lead sponsor
University of Houston
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 4 Interventional Results available

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

NCT04413279
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
LipiFlow Thermal Pulsation, Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
Procedure · Drug
Lead sponsor
Eye Surgeons of Indiana
Network
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction

NCT05162261
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
Interventions
Tixel C, LipiFlow
Device
Lead sponsor
Novoxel Ltd.
Industry
Eligibility
22 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
La Jolla, California • Newport Beach, California • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Dysfunction Management With ZEST Protocol

NCT03968731
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Ocular Surface Disease
Interventions
Zocular Eyelid System Treatment
Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Nov 10, 2026, 5:48 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Eyelid Androgen Treatment in Dry Eye

NCT06154200
View directory record Official record
Conditions
Aqueous Tear Deficiency, Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Interventions
Testosterone gel 4.5%, Vehicle gel
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

NCT04469998
View directory record Official record
Conditions
Posterior Blepharitis, Meibomian Gland Dysfunction
Interventions
AXR-270 Low Dose, AXR-270 High Dose, AXR-270 Vehicle
Drug
Lead sponsor
AxeroVision, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Nov 10, 2026, 5:48 PM EST
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

NCT01797107
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Azasite
Drug
Lead sponsor
Philadelphia Eye Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

NCT04884243
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
CBT-006
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

NCT05454956
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Northridge, California • Kansas City, Missouri • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease

NCT03658811
View directory record Official record
Conditions
Dry Eye
Interventions
intense pulsed light
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Nov 10, 2026, 5:48 PM EST
Not listed No phase listed Observational Accepts healthy volunteers

Evaluation of Ocular Surface Changes Following RF Electrocoagulation Treatment of the Periorbital Region

NCT03280069
View directory record Official record
Conditions
Skin Laxity, Meibomian Gland Dysfunction
Interventions
THERMIeyes® 20 RF System
Device
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
40 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Nov 10, 2026, 5:48 PM EST